CBLIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 9月 2021 @ 13:00):

Stats
本日の出来高	116 255
平均出来高	156 953
時価総額	226.39M
EPS	$-0.0426 ( 2021-08-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.436 (13.75%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-27	Selsky Clifford	Buy	101 579	Common Stock, par value $0.005 per share
2021-07-27	Aronstam Peter	Buy	141 370	Common Stock, par value $0.005 per share
2021-07-27	Selsky Clifford	Buy	0
2021-07-27	Aronstam Peter	Buy	0
2021-07-27	Barbarick Steve K	Buy	0

INSIDER POWER
0.00
Last 91 transactions
Buy: 2 702 906 \| Sell: 404 086

ボリューム相関

長: 0.15 (neutral)

短: -0.89 (strong negative)

Signal:(40.963) Neutral

Cleveland Biolabs Inc 相関

10 最も正の相関
HIBB	0.941
BEAT	0.933
HALO	0.926
BMRA	0.926
EMKR	0.925
VLCN	0.924
FNWD	0.912
PROV	0.911
GCBC	0.91
NDLS	0.909

10 最も負の相関
GPACU	-0.931
RXST	-0.928
MSAC	-0.926
TZPS	-0.925
KAII	-0.923
FRBN	-0.92
META	-0.919
MLAI	-0.919
ALPA	-0.916
AEAC	-0.916

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cleveland Biolabs Inc 相関 - 通貨/商品

-0.22
( neutral )

-0.81
( strong negative )

0.00
( neutral )

-0.54
( weak negative )

-0.62
( weak negative )

0.12
( neutral )

Cleveland Biolabs Inc 財務諸表

Annual	2020
収益:	$262 942
総利益:	$262.94 (0.10 %)
EPS:	$-0.190

FY	2020
収益:	$262 942
総利益:	$262.94 (0.10 %)
EPS:	$-0.190

FY	2019
収益:	$1.11M
総利益:	$0.00 (0.00 %)
EPS:	$-0.230

FY	2018
収益:	$1.14M
総利益:	$0.00 (0.00 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Cleveland Biolabs Inc

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.